All news

Gefitinib offers palliative care for advanced oesophegal cancer

Added: Wednesday 31 October 2012

The drug Gefitinib (Iressa) has not been found to improve survival in advanced oesophegal cancer, but could prove beneficial in a palliative care setting. The researchers are now working on identifying which patients would actually benefit from this. Analysis of biomarkers allows researchers to identify a subgroup of suitable patients. They have warned that using Gefitinib on unselected populations will have no benefit.